Survodutide 10mg
Investigational dual GLP-1 and glucagon receptor agonist studied for body weight management and metabolic liver disease.
Mechanism
Operates as a coordinated dual agonist targeting GLP-1 and glucagon receptors to attenuate caloric intake, slow gastrointestinal transit, and stimulate hepatic energy expenditure and lipid catabolism.
Dosing
Standard research titration starts at 600 mcg administered subcutaneously once per week.
Reconstitution
Reconstituting a 10 mg vial with 2.0 mL of bacteriostatic water yields a finished concentration of roughly 5.0 mg/mL (50 mcg per U-100 unit).
Storage
Store the unmixed lyophilized powder frozen at -20 °C protected from moisture, and once reconstituted, maintain refrigerated at 2–8 °C away from light for up to 28 days without freezing.
Mix & measure Survodutide 10mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Survodutide 10mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 16.7
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 600 mcg (1× weekly) | 12 units (0.12 mL) |
| Weeks 5–8 | 1200 mcg (1× weekly) | 24 units (0.24 mL) |
| Weeks 9–12 | 1800 mcg (1× weekly) | 36 units (0.36 mL) |
| Weeks 13–16 | 2400 mcg (1× weekly) | 48 units (0.48 mL) |
| Weeks 17–20 (optional) | 3600 mcg (1× weekly) | 72 units (0.72 mL) |
| Weeks 21–24 (optional) | 4800 mcg (1× weekly) | 96 units (0.96 mL) |
Reconstitution Steps
- 1
Draw 2.0 mL of bacteriostatic water into a sterile mixing syringe.
- 2
Introduce the liquid smoothly along the interior glass wall of the 10 mg vial to minimize agitation and froth formation.
- 3
Swirl or rotate the vial gently between the fingers until the cake is fully dissolved, strictly avoiding vigorous shaking.
- 4
Affix a label noting the reconstitution date and 5.0 mg/mL concentration, and transfer immediately to dark refrigerated storage at 2–8 °C.
Supplies Needed
Peptide Vial
Lyophilized survodutide 10 mg active ingredient container.
Insulin Syringes (U-100)
Fine-gauge 1 mL disposable syringes for precise micro-volume administration.
Bacteriostatic Water
Sterile diluent preserved with 0.9% benzyl alcohol for peptide reconstitution.
Alcohol Swabs
Antiseptic wipes to sanitize the rubber vial stopper and clean the application site.
Why researchers study it
Investigation into weight reduction and systemic energy homeostasis
Preclinical models of MASH and hepatic fibrosis resolution
Assessment of central satiety signaling and food intake regulation
Exploration of glucagon-mediated lipid oxidation and hepatic fat clearance
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Survodutide (designated BI 456906) is an advanced investigational synthetic peptide designed to simultaneously engage both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Jointly developed for metabolic research, this dual agonist represents a modern frontier in therapeutic exploration beyond traditional selective GLP-1 monotherapies. In laboratory research environments, this dual-pathway approach is examined for its potent capacity to moderate appetite signaling via GLP-1 agonism while concurrently boosting hepatic lipid turnover and resting caloric turnover via the glucagon pathway. Consequently, scientific interest is strongly directed toward its utility in managing high-mass metabolic models and non-alcoholic fatty liver conditions like metabolic dysfunction-associated steatohepatitis (MASH). Although it has advanced to Phase 3 evaluations such as the SYNCHRONIZE and LIVERAGE trials, survodutide remains an unapproved investigational research substance. It is strictly designated for scientific evaluation and in vitro or preclinical laboratory contexts, and is not permitted for human administration.
References
- 1.New England Journal of Medicine, Phase 2 trial in people with overweight or obesity — Dual glucagon/GLP-1 receptor agonist survodutide evaluation
- 2.The Lancet Diabetes & Endocrinology, Phase 2 dose-finding study — Dose-dependent weight loss with weekly survodutide
- 3.Molecular Metabolism, Pharmacological review — Dual GLP-1/glucagon receptor agonism on appetite, energy expenditure, and liver fat
- 4.New England Journal of Medicine, Phase 2 trial — Survodutide in metabolic dysfunction-associated steatohepatitis (MASH)
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allB7-33 10mg
A synthetic single-chain relaxin-2 mimetic engineered to selectively activate RXFP1 signaling for preclinical anti-fibrotic research.
View ProtocolTB-500 + BPC-157 5+5 mg
A dual-peptide research stack pairing TB-500 and BPC-157 in separate vials to investigate complementary soft-tissue and wound healing pathways.
View ProtocolFOXO4-DRI 10mg
FOXO4-DRI is an investigational D-retro-inverso peptide researched as a senolytic targeting p53 interactions in non-viable cells.
View Protocol